Abstract While breast cancer mortality rate has seen a steady decline in the last few decades, advances in better treatment and diagnostic tools remain important as we come into the age of personalized therapy. In this report, we describe our studies of SGK3's role in breast cancer. SGK3 (also known as CISK) is a member of the AGC family of kinases. Our previous work indicates that SGK3 functions downstream of the PI 3-kinase cascade and shares molecular and biochemical similarities with Akt.
Introduction
Improved screening and treatment has significantly reduced the mortality rates of breast cancer, the most commonly occurring cancer among women [1, 2] . Hereditary breast cancers can be attributed mostly to high-penetrance breast cancer susceptibility genes, for example, tumor suppressor genes BRCA1, BRCA2, p53, ATM, BARD1, and PTEN [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Sporadic breast cancer cases, which make up the majority of all breast cancers, are likely the results of low-penetrance risk factors working together with endogenous (e.g., hormones) and exogenous risk factors (e.g., pollution and diet). The inherent heterogeneity and complexity of breast cancer will continue to challenge researchers and clinicians in diagnosing and treating the disease.
Among the many genetic factors associated with cancer, the growth factor receptor (GFR)/PI 3-kinase cascade has been one of the most widely studied. Mutations of various components of the PI 3-kinase signaling pathway have been found in many types of cancers including breast cancer. These include the oncogenic amplification and overactivation of human EGFR family (HER) of receptor tyrosine kinases such as EGFR [13, 14] and HER2 [15, 16] , activating mutations and amplification of the gene that encodes the catalytic subunit of PI 3-kinase (p110) [17] [18] [19] , overexpression of PDK1 [20, 21] , activation of Akt genes [22, 23] , and germ-line and somatic mutations of the tumor suppressor PTEN [24, 25] . These observations indicate that players of the PI 3-kinase pathway are part of the cancer molecular signature and represent prime targets for potential anti-cancer drugs and therapies.
Clinically, estrogen receptor (ER) is one of the most important markers in breast cancer diagnosis and treatment. Nearly 70 % of all breast cancers express ER, where higher ER expression is often associated with better outcome for endocrine therapy. More recently, breast cancer research has benefited from laboratory technological advances that enable more nuanced classification of breast tumors both clinically and molecularly. For example, mature technologies such as microarray and more recently deepsequencing have enabled breast tumors to be divided based on an ever-expanding list of potential diagnostic and prognostic markers [26] [27] [28] [29] [30] [31] . Some of the most commonly seen tumors fall into the luminal A or B categories. Luminal A tumors are characterized by high ER/PR levels along with the low expression of proliferative markers such as Ki-67; luminal B tumors are often low for ER/PR, but higher for proliferative markers [32] . Molecularly, crosstalks between ER and PI 3-kinase/Akt pathways have also been shown to play a role in the development of drug resistance [33] [34] [35] [36] .
During our previous studies, we carried out an enhanced retroviral mutagen (ERM)-mediated genetic screen and identified the ser/thr kinase SGK3 (also known as CISK) as a survival kinase that functions downstream of the PI 3-kinase cascade [37, 38] . It is a member of the serumglucocorticoid-regulated (SGK) family protein kinases, as well as the AGC superfamily. We showed that SGK3 could protect cells from apoptosis induced by factor withdrawal [39] . Importantly, activated SGK3 can promote estrogen/ ER-dependent transcription and cell survival [39] . Recent studies using the MCF-7 breast cancer cell line support the model that SGK3 and ER form a feedback loop [40] . In this report, we provide further evidence for the feedback regulation between SGK3 and ER. Furthermore, this model was corroborated by our analysis of human breast tumor samples. Our data establish a clinical link between SGK3 and ER, and underline the importance of incorporating SGK3 as a new component in the assessment of breast cancer.
Materials and methods
Cell lines, constructs, and antibodies MCF-7L [39, 41, 42] cells were used for qRT-PCR, western blotting, and microarray analysis. Cells were cultured in DMEM supplemented with 10 % FBS. Alternatively, MCF-7 cells were maintained in phenol red-free DMEM media containing 10 % charcoal-stripped (CS) serum for 48 h, before the addition of 10 nM 17b-estradiol (E2) (Sigma-Aldrich). Cells were then collected at the indicated time points after addition of E2 for mRNA or protein expression analysis. Parental HEK293T cells and those transiently expressing activated SGK3 [37, 38] or SGK3 shRNA sequences [39] were used for antibody testing for immunohistochemistry analysis.
Real-time qRT-PCR and western blotting
Real-time quantitative PCR was performed as described previously [43] . Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA) for reverse transcription using the iScript cDNA Synthesis Kit (BioRad, Hercules, CA). Real-time qPCR amplification reactions were performed using the SYBR green master mix and an ABI StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA).
Cells were freshly lysed in lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 10 % glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.15 unit/ml aprotinin, 20 lM leupeptin, 1 mM sodium vanadate, 1 lM b-glycerol phosphate, and 1 lM dithiothreitol). Cell lysates were resolved by 8 % SDS-PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad). Rabbit polyclonal antibodies for SGK3 (against the PX domain) were generated by Bethyl Laboratories (Montgomery, TX). Anti-Rabbit-HRP was obtained from Bio-Rad.
Establishment of endocrine resistance breast cancer cell models
Two endocrine resistance cell models of T47D and BT483 were established in this study. Briefly, the ER? T47D and BT483 cells growing in full medium (RPMI-1640, 10 % FBS) were adapted in estrogen-deprived (ED) medium (phenol red-free RPMI-1640, 10 % CS-FBS), with or without the addition of 10 -7 M of 4-OH-tamoxifen (Tam) (Sigma-Aldrich) for [6 months. In contrast to parental cell lines that are sensitive to endocrine treatment (ED or Tam), the derivatives developed resistance phenotypes to ED (ED R ) or Tam (Tam R ) and exhibited regular growth rate (passaged twice/week with a ratio of 1:3). The endocrine resistant MCF-7 xenograft models have been previously published [41, 42] .
Patient tumor samples
A total of 133 patients, who underwent surgical excision between 2006 and 2011 at MDACC and had available formalin-fixed, paraffin-embedded tissue blocks of primary invasive breast carcinoma, were identified from the surgical pathology files in the Department of Pathology and included in this study. Patient age, tumor histologic type, pathologic tumor size, tumor histologic grade, prognostic/ predictive marker status, lymph node status, and the history of neoadjuvant chemotherapy were retrospectively recorded from the medical records. The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations were followed for scoring ER, progesterone receptor (PR), and HER2 [44, 45] , which were performed as part of the routine pathology evaluation. Briefly, ER and PR status were determined by immunohistochemical (IHC) staining with monoclonal antibodies against ER (6F11, Novacastra laboratories Ltd, Burlingame, CA) and PR (1A6, Novacastra Laboratories Ltd). Positive staining was defined as nuclear staining in at least 1 % of invasive cancer cells. HER2 status was tested by fluorescence in situ hybridization (FISH) with the PathVision kit (Vysis, Downers Grove, IL), or by IHC staining with a monoclonal antibody (AB8, Neomarkers, Fremont, CA). Triple-negative (ER negative, PR negative, and HER2 negative) was defined accordingly. In addition, Ki67 proliferation index performed as part of routine pathology evaluation by IHC (MIB-1, Dako, Carpenteria, CA) was recorded from the medical records whenever available. This study was approved by the institutional review board of MDACC.
SGK3 immunohistochemistry staining and evaluation
In each case, one whole slide of unstained tissue section (4-lm thick) that had been prepared from a representative paraffin block of a surgically excised primary invasive breast carcinoma was deparaffinized in xylene and rehydrated to 50 % ethanol. Antigen retrieval was achieved by pressure cooking the slide in 10 mM citric buffer (pH 6.0) for 5 min. Endogenous peroxidase activity was inactivated by treating the slide with 3 % H 2 O 2 for 5 min at room temperature. The slide was then washed and blocked for 1 h in 1 9 PBS containing 3 % normal non-immune goat serum to reduce non-specific staining. This was followed by incubating the slide with rabbit polyclonal anti-CISK PX antibody (5 lg/ml) overnight at 4°C, washing three times with 1 9 TBST, and incubation with EnVision? System-HRP-labeled anti-Rabbit polymer (DAKO) for 30 min at room temperature. Visualization was achieved by incubating slides with Liquid DAB? Substrate Chromogen System (DAKO) for 10 min at room temperature.
SGK3 expression was reviewed and recorded as the proportion of cells stained and staining intensity in the invasive carcinoma in each case. The results were evaluated by the Q score method [46] . The proportion of stained cells was scored as follows: \1 %, score 0; 1-25 %, score 1; 26-50 %, score 2; 51-75 %, score 3; and [75 %, score 4. The staining intensity was scored as follows: no staining, score 0; weak average staining, score 1; moderate average staining, score 2; and strong average staining, score 3. The Q score was generated from adding the proportion score and the intensity score, which led to a range of 0-7. A Q score of [2 was considered positive for SGK3.
Statistical analysis
All statistical tests were performed by R version 2.12.0 (http:www/r-project.org). For analyzing the correlation between two categorical variables, Fisher's exact test was used. Logistic regression was used to analyze the association between SGK3 positivity as defined above and factors of interest. A P value of \0.05 indicated statistical significance. Cox proportional hazards regression analysis was used to assess the association between SGK3 expression and patient survival.
Results

SGK3 functions as a classic ER-dependent gene
SGK3 appears to be widely expressed in a variety of tissues both in mice [38] and in human ( Supplementary Fig. S1 ). Previously, we have shown that SGK3 is crucial to estrogen-dependent growth of the ER? breast cancer cell line MCF-7 [39] , suggesting that SGK3 potentiates the transcriptional activation function and proliferative effect of estrogen/ER signaling. Using the MCF-7 cell line model, Wang et al. [40] provided evidence that SGK3 is an E2-dependent gene. To further explore the regulation of SGK3 by estrogen/ER, we examined the mRNA as well as protein expression of SGK3 in our MCF-7 cells [39] . Consistent with published data, when these cells were stimulated with the addition of estrogen, we observed increased expression of SGK3 proteins as well as mRNAs (Fig. 1a) . This estrogen/ER-dependent transcriptional activation could also be observed in additional ER? breast cancer cell lines (BT474 and T47D), when we analyzed gene expression data from our previously published studies (Fig. 1b) [47] . These findings support the model that SGK3 forms a feedback regulatory loop with ER.
Further corroboration came from our analysis of SGK3 expression under conditions that inhibited ER signaling. Here, we established two endocrine resistance cell models (T47D and BT483) (see ''Materials and methods'' section). As shown in Fig. 1c , protein expression of SGK3 was downregulated in these derivative cells (Tam R and ED R ) compared to their parental counterparts. Furthermore, in our previously reported MCF-7 xenograft mouse models of estrogen deprivation or tamoxifen treatment [41, 42] , the mRNA level of SGK3 was also significantly decreased (Fig. 1d) . When endocrine-resistant tumors eventually developed in these xenografted mice, SGK3 expression remained blocked (data not shown). Collectively, these data indicate that SGK3 bears the hallmarks of a classic ER-dependent gene that functions downstream of estrogen/ ER.
SGK3 expression in breast cancer patient samples
The analysis, thus far, suggests a strong correlation of SGK3 and ER expression. We then analyzed SGK3 expression in patients by the Oncomine Research database (http://www.oncomine.org) for gene expression studies involving C200 patients with known molecular subtypes based on PAM50 classification. Patients from the Hatzis dataset were found to have significantly higher SGK3 expression in the luminal A and B subtypes when compared to those in HER2, basal, or normal subtypes (Supplementary Fig. S2 ) [48] . When we examined SGK3 levels in a compendium of expression profiles (Affymetrix U133A) on 1,340 human breast tumors (which were compiled previously from published studies [49] ) we found lower SGK3 expression to associate with poorer prognosis and BT-474 cells from a previously published study [47] were plotted. c SGK3 protein expression was suppressed when ER was inhibited in breast cancer cells. Anti-SGK3 antibodies were used to western blot whole cell lysate from wildtype (WT) T47D and BT483 cells and their derivatives. NS non-specific band was used as loading control. ED Rresistant clones from estrogen deprivation treatment. Tam R -resistant clones of tamoxifen-treated cells. d SGK3 mRNA expression was suppressed when ER was inhibited in MCF-7 endocrine resistance cells. E2 estrogen treatment ( Fig. 2) (P \ 0.0001, univariate Cox). When we only examined ER? tumors (N = 686), an association between higher SGK3 level and better prognosis could still be observed, though the trend here was not as strong (P = 0.04, univariate Cox).
Validation of anti-SGK3 antibody for IHC analysis
To probe the link between SGK3 and ER expression in breast tumors, we next established a SGK3 IHC assay for clinical samples. We have previously generated an antibody against the unique N-terminal PX domain of SGK3 and successfully used it to western blot and immunoprecipitate SGK3 using cultured cells (Fig. 1a) [39] . To characterize the antibody for IHC, we generated 293T cells transiently expressing full-length-activated SGK3 (SGK3 OXP) [37, 38] , or shRNA sequences against SGK3 (SGK3 KD) [39] , and made formalin-fixed, paraffin-embedded pellets of these cells. As shown in Fig. 3 , our antibody could recognize both endogenous and exogenous SGK3 for IHC. More importantly, SGK3 antibody staining was significantly reduced in cells expressing SGK3 shRNA sequences. These results indicate that the antibody is suitable for IHC analysis of clinical breast cancer samples.
Distinct SGK3 expression patterns in breast tumor samples
To further investigate the role of SGK3 in breast cancer, we examined the expression of SGK3 in 133 clinical primary invasive breast carcinomas from 133 patients. All patients were women between the ages of 27 and 88 years (median, 55 years). The clinicopathologic features of these patients are summarized in Table 1 . The Q score distribution for SGK3 staining is summarized in Table 2 . In tumors with strong staining, simultaneous cytoplasmic and nuclear staining was noted (Fig. 4) . In tumors with weak or moderate staining, SGK3 expression appeared to be predominantly in the cytoplasm where simultaneous staining of the nucleus was only seen in rare cases. Scattered nonneoplastic breast epithelium was present at the periphery of the invasive carcinoma in 105 tumor samples that stained for SGK3. SGK3 expression was predominantly cytoplasmic in the surrounding non-neoplastic epithelium with rare cases showing both cytoplasmic and nuclear staining. Using a Q score of[2 as cutoff, positive staining for SGK3 was observed in 71 tumors (53 %) and in the surrounding non-neoplastic epithelium in 64 samples (61 %). As summarized in Table 1 , in univariate analyses, there was substantial evidence of an association between SGK3 staining and ER status, PR status, and triple-negative status of the tumor (P \ 0.0001). Patients with ER-positive, PR-positive, or non-triple-negative tumors were more likely to have positive SGK3 staining. In addition, there was a statistically significant association between SGK3 staining and tumor grade (P = 0.008) where patients with lower grade tumors were more likely to have positive SGK3 staining. An association between SGK3 staining and axillary lymph node status (P = 0.02) was also observed. Other clinicopathologic features were not significantly associated with SGK3 staining.
Factors that were significantly associated with SGK3 expression were fit in a multivariate model. Because ER and PR are highly correlated, and ER, PR, and HER2 are highly correlated with triple negativity, two separate multivariate models were considered: one with ER status and another with triple-negative status. In these models, ER status and triple negativity remained statistically highly significant factors associated with SGK3 expression (Tables 3, 4) . ER-positive patients were more likely to have positive SGK3 expression (P = 0.0002, OR = 6.18) and triple-negative patients were more likely to have negative SGK3 expression (P = 0.0007, OR = 0.19). Lymph node status was of marginal significance in both models (P = 0.05 and P = 0.08, respectively). Taken together, the findings indicate that SGK3 expression is significantly associated with ER status in human breast tumor samples.
Discussion
In this study, we explored estrogen/ER-dependent regulation of SGK3 in multiple ER? cell line models and in derivative cells that were resistant to tamoxifen or estrogen-deprivation treatment. Furthermore, we established for We have shown previously that SGK3 can positively regulate ER transcriptional activation in vitro [39] . This function depends on SGK3 kinase activity, which can be assessed by its phosphorylation status. Owing to the lack of an anti-phosphoSGK3 antibody suitable for IHC analysis, we were unable to assess the activation status of SGK3 in patient tumor samples. However, accumulating data support the model of a positive feedback loop between ER transcriptional activity and SGK3 expression and possibly enzymatic activation. Crosstalks between GFR/PI 3-kinase signaling and ER pathway have been well documented [33] [34] [35] [36] . It has been shown that PI 3-kinase pathway activation is inversely associated with ER expression and patient outcome [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . As a result, combination therapies that also target the GFR pathways may prove effective in combating endocrine therapy resistance. The expression profile of SGK3, however, appears to positively correlate with ER expression and better prognosis. Such observations underline the uniqueness of individual components of the PI 3-kinase cascade.
We initially identified SGK3 in a genome-wide screen for cell survival genes [38] . As a survival kinase downstream of the PI 3-kinase pathway, SGK3 shares both sequence and functional similarity with Akt, another AGC SGK3 OXP SGK3 KD parental Fig. 3 Analysis of anti-SGK3 antibody for IHC. Parental 293T cells and those transiently expressing activated SGK3 (SGK3 OXP, top) or an shRNA sequence against SGK3 (SGK3 KD, bottom) were harvested and used for IHC analysis family member. However, structurally and molecularly, there is clear non-redundancy between SGK3 and Akt. In place of the PH domain, SGK3 contains a PX domain that binds phospholipids with specificities distinct from the PH domain [38, 60] . One of the substrates shared between Akt and SGK3 is the pro-apoptotic protein BAD [61, 62] . BAD contains multiple potential phosphorylation sites for ser/thr kinases, and their phosphorylation is important for Bad function [63] . Even though the kinase domains for SGK3 and Akt exhibit extensive homology, the SGK3 phosphorylation sites on BAD differ from those for Akt [38] . Furthermore, proteomic analysis revealed that the SGK3 protein complex in cells differed from the Akt protein complex [64] , suggesting unique interaction, activity, and signaling to each of the two kinases. These observations underline the unique properties for SGK3 and Akt, both biochemically and at the cellular level.
While the role of Akt in breast cancer has been extensively studied, the function of SGK3 in breast cancer remains unclear. Our analysis of [1,000 tumor data revealed a positive correlation between SGK3 level and patient survival and prognosis. In comparison, no correlation between Akt mRNA expression and tumor prognosis was found in a previous analysis of breast tumors [50] . Such differences cannot be easily explained by our current knowledge of SGK3 and Akt, and are supported by findings from Vasudevan et al. [65] who demonstrated that SGK3 represents a non-redundant alternative pathway that is downstream of PI 3-kinase signaling and distinct from Akt in breast cancer cells. More in-depth studies that dissect the intrinsic signaling pathways mediated by these 
